48 results about "Uterine tissue" patented technology

A surgical fluid management system delivers fluid for distending a uterine cavity to allow cutting and extraction of uterine fibroid tissue, polyps and other abnormal uterine tissue. The system comprises a fluid source, fluid deliver lines, one or more pumps, and a filter for re-circulating the distension fluid between the source and the uterine cavity. A controller can monitor fluid retention by the patient.

A method and system of providing therapy to a patient's uterus. In some embodiments the method includes the steps of: inserting an access tool through a cervix and a cervical canal into the uterus; placing an expansion mechanism in contact with tissue within the uterus to move uterine tissue surfaces away from an opening in an access tool lumen; delivering vapor through the vapor delivery tool into the uterus; and condensing the vapor on tissue within the uterus. The system has an access tool adapted to be inserted through a human cervical canal to place an opening of an access tool lumen within a uterus when the access tool is inserted through the cervical canal; an expansion mechanism adapted to be advanced into the uterus to move uterine tissue surfaces away from the opening in the access tool lumen; and a vapor delivery mechanism adapted to deliver condensable vapor through the access tool to the uterus, the condensable vapor being adapted to condense within the uterus.

A system for treating uterine tissue having a seal assembly configured for positioning in a patient's cervical canal and uterine cavity; an expandable distal balloon portion; an expandable elongate medial balloon portion configured for movement between a first transversely expanded shape for engaging a cervical canal and a second transversely non-expanded shape for trans-cervical insertion; and a fluid source in communication with distal balloon portion and medial balloon portion for expansion of said balloon portions.

A method for photoselective vaporization of uterine tissue includes delivering laser radiation to the treatment area on the tissue, via an optical fiber for example, wherein the laser radiation has a wavelength and irradiance in the treatment area on the surface of the tissue sufficient because vaporization of a substantially greater volume of tissue than a volume of residual coagulated tissue caused by the laser radiation. The laser radiation is generated using a neodymium doped solid-state laser, including optics producing a second or higher harmonic output with greater than 60 watts average output power. The delivered laser radiation has a wavelength for example in a range of about 200 nm to about 650 nm, and has an average irradiance in the treatment area greater than about 10 kilowatts / cm2, in a spot size of at least 0.05 mm2.

A method and system of providing therapy to a patient's uterus. In some embodiments the method includes the steps of: inserting an access tool through a cervix and a cervical canal into the uterus; placing an expansion mechanism in contact with tissue within the uterus to move uterine tissue surfaces away from an opening in an access tool lumen; delivering vapor through the vapor delivery tool into the uterus; and condensing the vapor on tissue within the uterus. The system has an access tool adapted to be inserted through a human cervical canal to place an opening of an access tool lumen within a uterus when the access tool is inserted through the cervical canal; an expansion mechanism adapted to be advanced into the uterus to move uterine tissue surfaces away from the opening in the access tool lumen; and a vapor delivery mechanism adapted to deliver condensable vapor through the access tool to the uterus, the condensable vapor being adapted to condense within the uterus.

The invention provides a device and a compound for the prevention and / or treatment of uterine fibroids in human patients, wherein the compound is dispensed from the device and is administered locally to the uterine tissue.

The invention discloses a preparation method and an application of a tissue slice for observing temporal-spatial distribution of early embryo development in vivo. The preparation method comprises the following steps that 4% paraformaldehyde fixing, upward gradient ethanol dehydration, wax dipping, embedding, serial section, baking, dewaxing and downward gradient ethanol rehydration are performed in sequence on oviducts or uterine tissues which contain mice embryos in every period, and finally, after haematoxylin-eosin staining is performed on the tissues in the slice, neutral gum is used for sealing the slice, or after immunofluorescence histochemical staining is performed on the slice, a fluorescence resistant quenching sealing agent is used for sealing the slice. The tissue slice disclosed by the invention can be used for manufacturing a map of early mice embryo development and detecting the expression of Crb3 in the mice embryos in every period of development in vivo. The preparation method has the advantages that positions of all organs in the embryos can be relatively fixed, so that the position change of embryo cells in a genital tract and the continuity of embryo development can be conveniently observed, the structure is clear, and the tissue slice is convenient to store.

A method for photoselective vaporization of uterine tissue includes delivering laser radiation to the treatment area on the tissue, via an optical fiber for example, wherein the laser radiation has a wavelength and irradiance in the treatment area on the surface of the tissue sufficient because vaporization of a substantially greater volume of tissue than a volume of residual coagulated tissue caused by the laser radiation. The laser radiation is generated using a neodymium doped solid-state laser, including optics producing a second or higher harmonic output with greater than 60 watts average output power. The delivered laser radiation has a wavelength for example in a range of about 200 nm to about 650 nm, and has an average irradiance in the treatment area greater than about 10 kilowatts / cm2, in a spot size of at least 0.05 mm2.

The invention provides a devices, methods and systems to measure and record uterine tissue environment components such as pH during the course of uterine artery occlusion. The uterus becomes ischemic due to the occlusion thereof, and its pH drops sharply within minutes of uterine artery occlusion and remains relatively low for a period of time. The return of normal pH is an indicator of return of blood to the ischemic tissue. In use, a catheter with a pH measuring tip is advanced through the patient's vaginal canal and into the patient's uterine cavity until the pH measuring active electrode on the distal end of the catheter contacts or penetrates the uterine fundus. The active electrode detects the pH and a signal representing pH is transmitted to a pH recording and monitoring device which preferably displays the pH. The signal may be transmitted through a conductor or by a radio transmitter. Components other than pH may be monitored such a pCO2, and pO2.

The invention discloses Sca-1+ / CD34- uterine stem cells, which are separated from the uterus of a mammal. In the invention, the CD34 and Sca-1 are expressed in form of CD34- and Sca-1+. The separating method of the Sca-1+ / CD34- uterine stem cells comprises: screening CD34- cells from digested uterine tissues by using magnetic bead marked antibody against CD34; and separating Sca-1+ cells from CD34- cells by using magnetic bead marked antibody against Sca-1, and obtaining Sca-1+ / CD34- uterine stem cells. Experiments prove that the Sca-1+ / CD34- uterine stem cells are capable of inducing endothelial cells to form vascular structures and forming lots of functional blood vessels, and can restore tissue perfusion to a certain degree and reduce tissue damage; and in-vivo level proves the Sca-1+ / CD34- uterine stem cells have treatment effect on ischemic diseases and can be used in preparation of medicines for preventing or treating ischemic diseases.

The invention relates to an artificial uterus three-dimensional gel model used for researching development and differentiation of embryonic stem cells, belonging to the research field of tissue engineering and regenerative medicine, and mainly solving the problem that no ideal bionic model exists for the research of differentiation and development of embryonic stem cells in vitro. The in vitro reconstructed tissue engineered uterus is adopted as a research model of the differentiation and development of the embryonic stem cells, wherein the embryonic stem cells are inoculated on the surface or evenly combined inside the uterus lamella, the development environment of normal embryos in vivo is simulated to regulate the microenvironment of the growth and development of the embryonic stem cells, and the reconstructed uterus tissues are taken as the main body to carry out the research on differentiation and development of embryonic stem cells, thus disclosing the inherent law and mechanism of the differentiation and development of embryonic stem cells in vitro, and searching for new methods for directional differentiation of embryonic stem cells to the functional cells of important vital organs at the terminal differentiation period; and the research results have an important meaning to disclose the development of the embryos in the early period, and have important theoretical meaning and application values for the curing based on embryonic stem cells.

The invention provides a method for separating and purifying endometrial stromal cell and proceeding with large scale external culture, which improves the external purifying ratio and the breeding ability of endometrial stromal cell, adjusts the proliferative stage of endometrium and uterus physiology by treating adenotropic enthusiasm hormone and adenotropic ovulation hormone for the experimental animal, purifies the endometrial stromal cell with centrifuge method, establishes an external culture system with estrogen and gestagen in the cell purification and breeding, improves the breeding ability of the endometrial stromal cell, achieves a large scale breeding purpose and provides the abundant seed cell for the construction of the organizing engineer uterine tissue.

A uterine fibroid treatment device providing for localized delivery of one or more treatment drugs for treating various uterine conditions including, for example, uterine fibroids, abnormal uterine bleeding, pelvic adhesions and endometriosis. Generally, the uterine treatment device comprises a physical positioning element that can be inserted, positioned and maintained in close proximity to the uterine tissue to be treated. The treatment drugs delivered to the treatment location can include various combinations of anti-proliferative agents and angiogenesis inhibitors to provide different treatments concurrently. In some embodiments, the physical element can also serve the dual purpose of delivering the treatment drugs while simultaneously cutting off blood flow to a mature fibroid to initiate hypoxic / ischemic conditions within the mature fibroid.

The invention discloses a Chinese medicine preparation for treating primary dysmenorrheal, a preparation method and an application. The Chinese medicine preparation is composed of medicines of angelica, flos rosae rugosae, fennel fruits, ligusticum wallichii, red paenoy roots and the like. On the basis of traditional Chinese medicine syndrome differentiation and treatment theory, the Chinese medicine preparation for treating primary dysmenorrheal is prepared by combining years of clinical experience. The Chinese medicine preparation for treating primary dysmenorrheal is characterized in that according to characteristics of hormonal level change at each stage of a sexual cycle, medicine intervention is performed at the luteal regression stage, two hormone peaks in the whole sexual cycle process can be avoided, relative excited signal molecues at the local position of uterus tissue can be directly confronted, interference for feedback effect on thalamus-hypophysis-ovarian axis sex hormone is weakened, and thereby the effect of treating the primary dysmenorrheal can be exerted. The Chinese medicine preparation for treating the primary dysmenorrheal has special good effects on the diseases of dysmenorrheal and abnormal menstruation and the like caused by kidney energy loss, qi stagnation and blood stasis, congealing cold blood stasis, stomachache due to emotional depression and the hyperactive liver-qi attacking the stomach and damp and hot accumulation, the Chinese medicine preparation for treating the primary dysmenorrheal is widely applied to clinic and relieves pains of patients, and the effective rate can reach to 96%.

The invention discloses a uterine inversion correcting and resetting machine. The uterine inversion correcting and resetting machine comprises a silica gel guide barrel, a piston head and a push rod; the silica gel guide barrel is provided with a skeleton support with a straight barrel type structure, an inner cavity of the skeleton support is provided with a plurality of linkage supporting plates, the bottoms of the linkage supporting plates are in sliding connection with the surface of the inner cavity of the skeleton support through linkage supporting plate guide grooves formed in the skeleton support in the axial direction; the outer surface of the skeleton support is coated with a silica gel guide barrel silica gel layer, the upper end of the silica gel guide barrel silica gel layer adopts a flared structure which is internally provided with tractive positioning points and extends outwards, and the tractive positioning points are connected with the bottom ends of the linkage supporting plates through steel wires; and the piston head is arranged in the barrel-shaped inner cavity of the skeleton support and positioned above the linkage supporting plates. The uterine inversion correcting and resetting machine is convenient to operate, and can prevent endometrium from being folded excessively and reduce the infection probability on the premise of successfully pushing the inversed uterus tissue into an abdominal cavity, thereby being particularly suitable for uterine inversion operation in case that the placenta is positioned near the bottom of the uterus.

A compact multi-lumened hysteroscope, a single-use tissue resector, and a medical system employing the same for diagnosis and therapeutic treatment of uterine tissue, such as polyps and fibroids.

The present invention relates to non-steroidal progestins of the general formula (I) wherein R1 and R2 are independently of each other -H or -F, R3 is -CH3 or -CF3, and Ar is or a pharmaceutically acceptable derivative or analogue thereof. These progestins are suitable for selectively modulating progesterone receptor mediated effects in different target tissues, particularly in uterine tissue versus breast tissue. Therefore, the progestins of the present invention, optionally in combination with estrogens, may be used for contraception (in particular in estrogen-free oral contraceptives), hormone replacement therapy and the treatment of gynecological disorders. The present invention furthermore relates to methods for selectively modulating progesterone receptor mediated effects in different target tissues or organs.

An object of the present invention is to provide a cell composition for treatment of uterine tissue that heals damage occurring in uterine tissue, including intrauterine adhesion, to a state that enables pregnancy. In addition, an object of the present invention is to provide a method for producing this cell composition for treatment of uterine tissue, and a cell composition for treatment of uterine tissue produced according to that method. The cell composition, which has a first cell layer containing epithelial cells and a second cell layer containing stromal cells, and the first cell layer is laminated on the second cell layer, has the ability to heal damage occurring in uterine tissue, including intrauterine adhesion, and restore it to a state that enables pregnancy.

A method for freeze-drying a biological sample of mammalian cells or tissue including placing a biological sample on or in a structure to increase a temperature of the biological sample and with the biological sample in a closed chamber applying a vacuum to the chamber to lower a pressure within the chamber, cooling the chamber to lower a temperature within the chamber and applying heat to the biological sample within the chamber. The biological sample can include one or more of stem cells, hematopoietic stem cells, mesenchymal stem cells, embryonic stem cells, induced pluripotent stem cells, sperm, oocytes, embryos, ovarian tissue, uterine tissue or testicular tissue.

The invention relates to a lower uterine segment hemostat, and belongs to the technical field of a medical device. The lower uterine segment hemostat provided by the invention can cover and immobilize entire cervix uterus and lower uterine segment and can take an effective hemostatic effect; and meanwhile, by arranging a locating clip, an external cervical orifice in the tail end of the lower uterine segment can be accurately located and immobilized, so as to facilitate a hemostasis operation and to improve the hemostatic effect. Moreover, the hemostat is provided with a tightening belt, so that the tightness degree of the hemostat can be controlled and regulated, and the lower uterine segment can be effectively contracted and blood vessels of the lower uterine segment can be compressed so as to achieve a combined hemostasis purpose. When the lower uterine segment is well contracted and a bleeding amount is reduced, the hemostat can be taken down more easily, and the cervix uterus and uterus tissues can be protected from being hurt.

The invention discloses a method for in-vitro induced decidualization of mouse uterus primary stroma cells. The method includes the following operation steps of firstly, taking a tissue block of uterus tissue of a mouse in the fourth day after the mouse normally gives birth; secondly, digesting the tissue block to obtain a single-cell suspension of the mouse uterus primary stroma cells; thirdly, culturing the single-cell suspension until the cell density reaches 75-85% for combination, exchanging fluid, removing parenchyma cells, and adding an induction medium for inducing the decidualizationof the mouse uterus primary stroma cells. The method is simple in operation, the mouse uterus primary stroma cells separated out can have a high survival rate, meanwhile the decidualization startup success rate is high, and a foundation is laid for the research of researches on the decidualization mechanism.

The invention relates to an experimental method for treating POI by combining ASP with hAD-MSCs. The experimental method comprises the following steps: preparing ASP drug-containing serum; adding ASP drug-containing serum with different concentrations into a culture medium to culture hAD-MSCs; and carrying out hAD-MSCs transplantation; 5) carrying out experiment grouping; observing ultrastructure change of each level of follicles and endometrium by using an electron microscope; carrying out immunohistochemical determination on the expression of a granular cell surface marker Fshr and an oocyte surface marker DDX4; and using an Elisa method for determining secretion conditions of antioxidant enzymes and oxidation products ROS, SOD and the like of the ovary and uterus tissues; (13) carrying out Western-blot determining and obtaining the change condition of the phosphorylation level; determining apoptosis conditions of follicular granular cells and oocytes by Tunel staining; determining the expression of the ovarian tissue FOXO3a through immunofluorescence double labeling; and 16) carrying out a cage closing experiment. The method has the advantages that the angelica polysaccharide is combined with the hAD-MSCs to improve the proliferation of stem cells, the microenvironment of the radioactive POI can be improved, the migration homing and local survival rate of the stem cells can be promoted, the treatment effect of the stem cells on the radioactive POI can be improved, and the method has a good popularization prospect.